BIOPHARMA CREDIT DL -,01

BioPharma Credit has announced an interim dividend of 1.75 cents per share for the quarter ended 30 June; payment will be made on 31 July to shareholders registered by 3 July (ex‑date 2 July). The company reaffirms its target annual base dividend of 7 cents, to be paid in four quarterly instalments, and does not rule out additional special dividends in the third and fourth quarters. Payments are normally made in US dollars (an election to receive British pounds is possible until 3 July) and the distribution has been classified as interest for UK tax purposes; the stock was last quoted at 95.40 cents. » More on de.investing.com

BioPharma Credit, through a subsidiary and BioPharma Credit Investments V, enters a senior secured loan agreement with Idorsia for up to CHF 75m (plus up to CHF 175m from BioPharma‑V). The disbursement is in three tranches (Tranche A CHF 45m ten business days after signing, Tranche B CHF 15m by 31.12.2026, Tranche C CHF 15m by 30.06.2027 subject to net‑revenue milestones) with maturity to June 2031. CHF portions bear interest of 7.00% p.a., USD portions at 3M‑SOFR + 5.75% (SOFR floor 3.25%); a one‑time fee of 1.5% is charged on disbursement; Idorsia will hedge FX risks via forward contracts. » More on de.investing.com

BioPharma Credit, through a wholly owned subsidiary, is providing Mineralys with a senior secured loan of up to $150 million and will act as collateral manager. In parallel, BioPharma Credit Investments V (Master) LP is investing an additional $350 million. The financing is structured in four tranches (Tranche A: $30 million paid immediately), runs until June 2031, bears interest at 3‑month SOFR plus 5.50% (SOFR floor 3.25%) and imposes a one‑time fee of 2.00% on the drawdown of each tranche, along with prepayment and make‑whole provisions. » More on de.investing.com